Antidiarrheal Prophylaxis Optimizes Neratinib Use in HER2+ Breast Cancer

Caroline Seymour
Published: Tuesday, May 07, 2019
Martin Dietrich, MD, PhD

Martin Dietrich, MD, PhD

Early prophylactic interventions have offset initial concerns regarding the incidence and severity of neratinib (Nerlynx)-associated diarrhea seen in the ExteNET trial, explained Martin Dietrich, MD, PhD, giving patients with HER2-positive breast cancer at high risk of recurrence a better chance of completing the full 1 year of extended adjuvant therapy and reducing their risk of developing invasive disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x